NPR logo

With PSA Testing, The Power Of Anecdote Often Trumps Statistics

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
With PSA Testing, The Power Of Anecdote Often Trumps Statistics


With PSA Testing, The Power Of Anecdote Often Trumps Statistics

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript


This is ALL THINGS CONSIDERED from NPR News. I'm Melissa Block.

Millions of men and their doctors are trying to understand new recommendations by a federal task. They advise against routine use of a blood test for prostate cancer test, the PSA test. The guideline raises some bigger questions: How should we interpret medical statistics and what role should expert panels should play in determining how doctors practice?

NPR's Richard Knox explains why it's so hard to answer those questions.

RICHARD KNOX, BYLINE: Tom Fouts and his doctor had been watching his PSA level creep up for almost two years, and he was losing sleep over it.

TOM FOUTS: My fear is in the middle of the night that this, you know, this is a silent killer. What if? What if? What if?

KNOX: Finally, he decided to act. Doctors did three painful biopsies and discovered a medium-grade cancer. He had surgery to remove it. Today, Tom Fouts is fine and he's convinced the PSA test was a lifesaver.

FOUTS: I'm a firm believer the PSA assay saved my life.

KNOX: And he doesn't think much of the U.S. Preventive Services Task Force, which last week recommended against routine PSA testing after analyzing reams of statistics.

FOUTS: My theory on statistics is anybody can look at the same stats and come up with their own opinion on it. Government does it. Each political party does it. Whatever you want it to come up to read, you can fine-tune it and make it come up to that.

KNOX: Hal Arkes says Fouts' way of thinking is nearly universal. Arkes is a professor of psychology at the Ohio State University.

HAL ARKES: Statistics are dry and they're boring and they're hard to understand, and they don't have the impact of someone standing in front of you telling their heartrending story. So I think this is common to just about everybody.

KNOX: The power of the anecdote almost always overwhelms statistical analysis, he says. Arkes suggests people do a mental exercise to understand what the numbers are saying about PSA.

Imagine a thousand men who had PSA screening tests in one auditorium, and a thousand who didn't in another. That represents the kind of studies the federal task force was relying on.

ARKES: Take a look at the men in the two auditoriums, the men in the screened and the men in the not-screened auditorium, there are just as many men who died from prostate cancer in each auditorium - which leads us to think that in the aggregate it didn't do any good.

KNOX: Arkes spells it out in the journal Psychological Science. In each auditorium, there would be eight men who'd died of prostate cancer. But among the thousand who got PSA tests, there would also be 20 men who got treated for prostate cancers that would never have grown and caused symptoms. And five of these needlessly treated men would have lifelong complications, such as impotence and incontinence.

DR. IAN THOMPSON: That article is exactly correct.

KNOX: That's Dr. Ian Thompson, a urologist at UT, San Antonio medical center. He says Arkes's numbers are right, according to the current clinical trials of PSA screening.

THOMPSON: If you leave them the way they are, that article is smack-on correct. But the trials had problems.

KNOX: Thompson says the chief issue is that men in the biggest and best study, from Europe, have been followed for a maximum of 13 years and that's not long enough.

THOMPSON: When you analyze those trials very early, what you pick up on are the harms of testing. And it really takes many, many years to see the benefits.

KNOX: He doesn't know how much longer the European men would need to be watched before it's clear that PSA testing did save many more from a prostate cancer death. But he doesn't think the Preventive Services Task Force should have taken a stand against testing at this time.

Dr. Michael Barry thinks Thompson has a point.

DR. MICHAEL BARRY: I'm reluctant myself to make a decision for someone else about PSA screening. And as a result, I'm also reluctant for expert panels to take that position of telling men what to do here.

KNOX: Barry is a Boston expert on medical decision-making.

BARRY: For me, the way out of this controversy is one man at a time.

KNOX: That is, doctors need to lay out the evidence as clearly as they can, which currently says there's very little, if any, benefit to PSA testing.

BARRY: I think many men won't want the test in that circumstance. But some still will and I'm comfortable with that.

KNOX: Up to now, Barry says, those discussions haven't been happening nearly enough.

Richard Knox, NPR News, Boston.

Copyright © 2012 NPR. All rights reserved. Visit our website terms of use and permissions pages at for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.